Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Macrogenics (MGNX) EBT Margin (2016 - 2025)

Macrogenics (MGNX) has disclosed EBT Margin for 14 consecutive years, with 36.22% as the latest value for Q4 2025.

  • On a quarterly basis, EBT Margin fell 3.0% to 36.22% in Q4 2025 year-over-year; TTM through Dec 2025 was 52.43%, a 8274.0% increase, with the full-year FY2025 number at 50.36%, down 634.0% from a year prior.
  • EBT Margin was 36.22% for Q4 2025 at Macrogenics, down from 23.09% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 23.09% in Q3 2025 to a low of 1686.79% in Q2 2024.
  • A 5-year average of 322.65% and a median of 303.85% in 2021 define the central range for EBT Margin.
  • Peak YoY movement for EBT Margin: crashed -133861bps in 2024, then skyrocketed 151791bps in 2025.
  • Macrogenics' EBT Margin stood at 411.65% in 2021, then soared by 104bps to 16.39% in 2022, then crashed by -2908bps to 460.39% in 2023, then surged by 92bps to 36.19% in 2024, then decreased by 0bps to 36.22% in 2025.
  • Per Business Quant, the three most recent readings for MGNX's EBT Margin are 36.22% (Q4 2025), 23.09% (Q3 2025), and 168.88% (Q2 2025).